Home Ubiquitin p97 inhibitor - Tyrosinase inhibitor - Syk inhibitor - Src inhibitor MNS (3,4-Methylenedioxy-β-nitrostyrene) For research use only.

MNS (3,4-Methylenedioxy-β-nitrostyrene)

Synonyms: MDBN

MNS is a tyrosine kinase inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.

MNS (3,4-Methylenedioxy-β-nitrostyrene) Chemical Structure

MNS (3,4-Methylenedioxy-β-nitrostyrene) Chemical Structure

CAS No. 1485-00-3

Purity & Quality Control

MNS (3,4-Methylenedioxy-β-nitrostyrene) Related Products

Signaling Pathway

p97 Signaling Pathways

p97 Signaling Pathway

Biological Activity

Description MNS is a tyrosine kinase inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.
Features The nitro group of MNS (3,4-Methylenedioxy-β-nitrostyrene) is essential for its antiplatelet effect.
Targets
p97 [2] Syk [1] Src [1]
1.7 μM 2.5 μM 29.3 μM
In vitro
In vitro MNS (3,4-methyl-enedioxy-β-nitrostyrene) completely inhibits 2 μM U46619-(a thromboxane A2 mimic), 5 μM ADP-, 100 μM arachidonic acid-(AA), 10 μg/ml collagen-, and 0.1 U/ml thrombin-induced platelet aggregation in a concentration-dependent manner with IC50 of 2.1 μM, 4.1 μM, 5.8 μM, 7.0 μM, and 12.7 μM, respectively. MNS inhibits platelet aggregation caused by either the calcium ionophore A23187 (1 μM) or the protein kinase C (PKC) activator PDBu (200 nM) with IC50 of 25.9 μM and 4.8 μM, respectively. MNS (20 μM) decreases dthrombin-induced P-selectin expression on platelets to levels comparable to those observed in PGE1-treated platelets. MNS (20 μM) markedly inhibits thrombin-but not PDBu-induced MARCKS phosphorylation in platelets. MNS (20 μM) markedly inhibits protein tyrosine phosphorylation at either 0.5 min or 3 min after thrombin or collagen stimulation in platelets. [1] MNS stimulates UbG76V-GFP and ODD-Luc degradation with IC50 of 1.6 μM and 5.9 μM, respectively. MNS inhibits MG132-induced accumulation of the reporter with IC50 of 2.1 μM. [2] MNS inhibits Gram-positive (Staphylococcus aureus and Enterococcus faecalis) and Gram-negative (Escherichia coli and Pseudomonas aeruginosa) bacteria with minimum inhibitory concentrations (MICs) of 128 mg/L. [3] MNS is much more potent than genistein in inhibiting platelet aggregation and protein tyrosine phosphorylation. MNS (3,4-Methylenedioxy-β-nitrostyrene) is equally potent as inhibitors of platelet aggregation as 3,4-dimethoxy-β-nitrostyrene. MNS (20 μM) concentration-dependently prevents ATP release from platelets stimulated by thrombin or collagen. MNS (20 μM) inhibits thrombin-induced PAC-1 binding to human platelets. [4]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04473027 Terminated
Melanoma|Cancer
University Hospital Ghent|Jessa Hospital|University Hospital Antwerp|Algemeen Ziekenhuis Maria Middelares|GZA Ziekenhuizen Campus Sint-Augustinus|AZ Sint-Jan AV|AZ Nikolaas|AZ Sint-Lucas Gent|AZ Sint-Lucas Brugge|General Hospital Groeninge|OLV van Lourdes Hospital Waregem|AZ Damiaan|AZ Delta|ASZ Aalst|Belgian Red Cross
 September 1 2020 --
NCT01362244 Completed
Nasal Polyps
GlaxoSmithKline
 May 12 2009 Phase 2
NCT00474799 Completed
Healthy
Javelin Pharmaceuticals
 January 2007 Phase 1

Chemical Information & Solubility

Molecular Weight 193.16 Formula

C9H7NO4
CAS No. 1485-00-3 SDF Download MNS (3,4-Methylenedioxy-β-nitrostyrene) SDF
Smiles C1OC2=C(O1)C=C(C=C2)C=C[N+](=O)[O-]
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 39 mg/mL ( (201.9 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy MNS (3,4-Methylenedioxy-β-nitrostyrene) | MNS (3,4-Methylenedioxy-β-nitrostyrene) supplier | purchase MNS (3,4-Methylenedioxy-β-nitrostyrene) | MNS (3,4-Methylenedioxy-β-nitrostyrene) cost | MNS (3,4-Methylenedioxy-β-nitrostyrene) manufacturer | order MNS (3,4-Methylenedioxy-β-nitrostyrene) | MNS (3,4-Methylenedioxy-β-nitrostyrene) distributor